DGAP-News: Correction of the Corporate News of March 15, 2019, 12:40 pm: Epigenomics AG: ?U.S. Representatives Payne and Marchant Introduce Bi-Partisan Colorectal Cancer Detection Bill


Nachricht vom 15.03.201915.03.2019 (www.4investors.de) -


DGAP-News: Epigenomics AG / Key word(s): Miscellaneous

Correction of the Corporate News of March 15, 2019, 12:40 pm: Epigenomics AG: ?U.S. Representatives Payne and Marchant Introduce Bi-Partisan Colorectal Cancer Detection Bill
15.03.2019 / 14:45


The issuer is solely responsible for the content of this announcement.
Correction of the Corporate News of March 15, 2019, 12:40 pm:U.S. Representatives Payne and Marchant Introduce Bi-Partisan Colorectal Cancer Detection Bill

Legislation aims to provide coverage under the Medicare program for FDA-approved qualifying colorectal cancer screening blood-based tests

Berlin (Germany) and San Diego, CA (U.S.A.), March 15, 2019 - Representatives Donald Payne, Jr (D-NJ) and Kenny Marchant (R-TX) today introduced the ''Donald Payne Sr. Colorectal Cancer Detection Act'' (HR 1765) to the United States House of Representatives in Washington D.C. This House Bill aims to provide payment and coverage under the Medicare program for FDA-approved qualifying colorectal cancer (CRC) screening blood-based tests.

"Screening utilizing blood testing mitigates patient barriers associated with typical colorectal cancer screening methods. The House Bill addresses the last barrier for Medicare patients - payment," said Greg Hamilton, Chief Executive Officer of Epigenomics AG. "The passing of this bill provides millions of unscreened Americans access to CRC screening and ultimately saves thousands of lives."

 

About colorectal cancer (CRC)

Colorectal cancer remains a leading cause of cancer death in the United States. Although screening and early detection of colorectal cancer can save lives, about 35% of eligible U.S. patients are not being screened regularly. The unscreened population disproportionately results in 43% of new CRC cases and about 76% of CRC deaths and the associated costs. Approximately $18 billion is spent annually on this preventable disease in the U.S. Thereof, over $13 billion is spent on cases from unscreened individuals.

By increasing screening and detecting more cancers early, the costs and deaths from this disease both can be addressed. The addition of the blood-based methods to the Medicare covered services would increase screening access in both urban and rural areas where populations are less likely to be screened.

The Payne/Marchant effort is a bipartisan effort to address appropriate use of health care resources.

About Epi proColon(R)

Epi proColon(R) is indicated for colorectal cancer screening in average-risk patients who are unwilling or unable to perform colorectal cancer screening by colonoscopy and stool-based methods.

For patients, the test only requires a simple blood sample draw as part of routine healthcare provider visits. There are no dietary restrictions or alterations in medication required for the test. The sample will be analyzed at a national or regional diagnostic laboratory.

For more information on Epi proColon, visit www.epiprocolon.com.

About Epigenomics

Epigenomics is a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology. The company develops and commercializes diagnostic products across multiple cancer indications with high medical need. Epigenomics' lead product, Epi proColon, is a blood-based screening test for the detection of colorectal cancer. Epi proColon has received approval from the U.S. Food and Drug Administration (FDA) and is currently marketed in the United States, Europe, and China and selected other countries. Epi proLung(R) and HCCBloodTest, blood-based tests for lung and liver cancer detection, has received CE mark in Europe.

For more information, visit www.epigenomics.com.

 

Contact in the U.S.
David Bull
Director of Marketing
Phone: 240.912.6430David.Bull@Epigenomics.com

Contact Epigenomics AG
Frederic Hilke
IR.on AG
Phone +49 221 9140 970ir@epigenomics.com

Epigenomics legal disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.












15.03.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language:
English
Company:
Epigenomics AG

Geneststraße 5

10829 Berlin


Germany
Phone:
+49 30 24345-0
Fax:
+49 30 24345-555
E-mail:
ir@epigenomics.com
Internet:
www.epigenomics.com
ISIN:
DE000A11QW50
WKN:
A11QW5
Listed:
Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange

 
End of News
DGAP News Service




788081  15.03.2019 











Aktuelle Nachrichten aus der 4investors-Redaktion

26.03.2019 - Gamigo: Anleihe wird aufgestockt
26.03.2019 - Steinhoff International will bei KAP Industrial aussteigen
26.03.2019 - JDC Group: Great-West Lifeco wird neuer Großaktionär
26.03.2019 - Co.Don: Neuer Vorstand
26.03.2019 - Wirecard Aktie explodiert - Anwaltskanzlei entlastet das Unternehmen
26.03.2019 - Wirecard Aktie: Der Untersuchungsbericht ist da
26.03.2019 - MyBucks: „Finanziell angespannte Situation”
26.03.2019 - RIB Software: Auftrag von Heinz von Heiden
26.03.2019 - Aves One: Profitabilität soll weiter steigen
26.03.2019 - BHB Brauholding kündigt Dividende an


Chartanalysen

26.03.2019 - Medigene Aktie: Und wie geht es nun weiter?
26.03.2019 - Bayer Aktie: Verkaufssignal oder Bärenfalle?
26.03.2019 - BASF Aktie: Gelingt jetzt wieder die Wende nach oben?
25.03.2019 - Baumot Aktie: Jetzt entscheidet sich sehr viel!
25.03.2019 - Paragon Aktie: Das wird jetzt sehr interessant
25.03.2019 - Mologen Aktie stürzt weiter ab: Wackelt jetzt die Kapitalerhöhung?
25.03.2019 - Bayer Aktie: Das könnte dramatisch werden
25.03.2019 - Commerzbank Aktie: Achtung, das könnte was werden!
22.03.2019 - Steinhoff Aktie: Das sind sehr interessante Beobachtungen!
22.03.2019 - Commerzbank Aktie hält wichtige Marke - Trendwende perfekt?


Analystenschätzungen

26.03.2019 - Nordex: 9,60 Euro oder 14,00 Euro?
26.03.2019 - K+S: Dreifaches Kaufvotum für die Aktie
26.03.2019 - Wirecard: Plus 76 Prozent
26.03.2019 - SFC Energy: 2019 soll Gewinn bringen
26.03.2019 - E.On: Deal fließt ein
26.03.2019 - Allgeier: Prognose ist machbar
26.03.2019 - Basler: Gedämpfte Aussichten
26.03.2019 - Freenet: Hohe Dividendenrendite aber kaum Aufwärtspotenzial
26.03.2019 - DWS Group: Aktie wird abgestuft
26.03.2019 - Salzgitter: Dividende überrascht


Kolumnen

26.03.2019 - House of Commons übernimmt das Ruder: Auf dem Weg zum Exit vom Brexit!? - Nord LB Kolumne
26.03.2019 - Kleiner Lichtblick beim Ifo-Geschäftsklimaindex - Commerzbank Kolumne
26.03.2019 - S&P 500: Bewährungsprobe für die Käufer - UBS Kolumne
26.03.2019 - DAX: Gelingt der erneute Konter? - UBS Kolumne
25.03.2019 - Ifo-Geschäftsklima: Ein überraschendes Lichtlein der Hoffnung! - Nord LB Kolumne
25.03.2019 - Amazon Aktie: Erholungsrally hat noch Potenzial - UBS Kolumne
25.03.2019 - DAX: Bullen unter Druck - UBS Kolumne
25.03.2019 - DAX im Abwärtssog: Inverse Zinsstruktur und Konjunktursorgen - Donner & Reuschel Kolumne
22.03.2019 - Steiler Bund & fallende Renditen: „Japanische Verhältnisse“ in Europa - Donner & Reuschel Kolumne
22.03.2019 - Weltwassertag: Investment in eine knappe Ressource - AXA IM Kolumne